TLR3 C1234T Polymorphism Classification for IPF Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods cannot predict the progression of idiopathic pulmonary fibrosis (IPF) or guide appropriate therapy, as the aggressiveness of the disease varies significantly among patients.
Innovation Solution
Identification of a specific single nucleotide polymorphism (SNP) in the toll-like receptor 3 (TLR3) gene, specifically the C1234T polymorphism, allows for classification of IPF patients into aggressive or moderate phenotypes based on their genotype, using genetic testing to determine homozygous (Phe/Phe), heterozygous (Leu/Phe), or wildtype (Leu/Leu) status, enabling prognosis and treatment guidance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genetic testing for TLR3 polymorphism is performed to classify IPF patients, then prognostic accuracy is improved, but diagnostic complexity increases
Solution Approach 1:
The invention extracts and focuses on a specific genetic marker (TLR3 C1234T polymorphism) from the complex landscape of IPF pathology. By isolating this single polymorphic site as the predictive marker, the method achieves high prognostic accuracy while avoiding the need to analyze multiple genetic variants or complex molecular pathways, thus resolving the contradiction between precision and complexity
Solution Approach 2:
The invention changes the diagnostic parameter from general clinical observation to specific genotypic classification. By defining three discrete genotype categories (CC, CT, TT) with corresponding phenotypic outcomes, the method transforms a continuous complex disease process into discrete, easily classifiable parameters that maintain high prognostic value while simplifying diagnostic interpretation
2Loss of information
If TLR3 genotype determination is used to predict disease progression, then information completeness is improved, but testing difficulty increases
Solution Approach 1:
The invention creates a simplified genetic copy or surrogate marker (the TLR3 polymorphism) that reflects the underlying disease progression mechanism. Instead of directly measuring complex disease processes like fibrosis progression or inflammatory activity, the method uses this genetic copy as a proxy, providing complete prognostic information through a relatively simple genotyping assay
Solution Approach 2:
The invention performs preliminary genetic characterization at the molecular level before clinical disease progression occurs. By determining the TLR3 genotype early in the disease course, the method provides advance information about disease trajectory, treatment response, and prognosis without requiring complex longitudinal monitoring or invasive procedures
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention concerns methods of classifying patients having idiopathic pulmonary fibrosis (IPF) and of determining a preferred therapy for the treatment of IPF based on the presence or absence of the C1234T polymorphism in the toll-like receptor 3 (TLR3) gene of such patients.